Patrick Campbell

Allergan announced approval of the sBLA for treatment in children from the ages of 2 to 17.

Investigators examined anti-VEGF injections claims data among Medicare Part B beneficiaries from 2012 to 2015 and found that aflibercept injections increased by 69% during that time.

A recent study reviewed operating times of ophthalmic procedures before and after transition to a new EHR system in 2 outpatient departments and an ambulatory surgical center.

Analysis of the SURTAVI clinical trial revealed that TAVR and SAVR are both safe for patients with a CABG history.

Survey of 3000 found that more than half of all respondents wish they knew more about heart failure but just 1 in 5 were likely to speak with their doctor out of fear of diagnosis or cost.

A recent study from investigators at Michigan State University found that vitamin D supplementation was not associated with reduced risk of major cardiovascular events.

Christopher Sorli, MD, vice president of medical affairs at Sanofi, discusses the results of a recent trial examining insulin glargine plus lixisenatide.

After Janssen's submission of an sNDA in March, results of the CREDENCE subgroup analyses were among the most anticipated presentations at ADA 2019.

A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.

FDA has announced the approval of liraglutide injections for treatment of type 2 diabetes among pediatric patients.

A 6-month study examining the effects of hepatic-directed prandial insulin in patients with type 1 diabetes mellitus was presented at ADA 2019.

Osama Hamdy, MD, PhD, discusses the impact of a 10-year study observing the impact of lifestyle interventions among diabetes patients in real-world clinical practice.

Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.

A study analyzing the renal outcomes of the DECLARE-TIMI 58 trial were presented at ADA 2019 in San Francisco, CA.

A recent analysis of the BRIGHT trial examining renal function of insulin glargine 300u/mL versus insulin degludec 100u/mL was presented at ADA 2019.

After making the rounds at ADA 2019, Patrick Burgess, MD, discusses what he thinks is the most important discussion taking place at this year's conference and the biggest challenge facing diabetes patients.

An analysis of 7 trials examining cardiovascular outcomes of study drugs found that concomitant insulin use increased a patient’s risk of severe cardiovascular outcomes.

A meta-analysis of 3 real-world studies into the effectiveness of Abbot's FreeStyle Libre Flash Glucose Monitoring System at ADA 2019.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.

An analysis of results from the EXSCEL trial has suggested that exenatide with SGLT2 inhibitors may reduce major cardiovascular events and improve renal health.

A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.

A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.

UNC professor of medicine discusses her thoughts on the largest challenges for physicians to overcome in the future of diabetes treatment.

Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.

Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.